5. Conclusions
NSCLC, tumor
TUMOR, NSCLC
In previously treated advanced NSCLC patients, baseline levels and dynamic changes in blood-based biomarkers can predict the efficacy of atezolizumab. ctDNA can provide a snapshot of the overall genomic profiling for advanced NSCLC and overcome the bias from an individual tumor biopsy. These ctDNA-based biomarkers are easily accessible by using validated NGS panels for NSCLC. This comprehensive analysis of blood-based biomarkers could aid in identifying NSCLC patients who would benefit from ICI in the initial phase of treatment. It may also provide an informative insight into the complex tumor heterogeneity and propose futuristic solutions.